|
195 Companies |
|
327 Products |
|
327 Products |
|
167 Mechanisms of Action |
|
13 Trials |
|
3266 News |
|
| «12...1920212223242526272829...6768» |
- New trial: UK-PK: National Study of a Pharmacokinetic-Focused Educational Package for Patients With Severe Haemophilia A (clinicaltrials.gov) - Aug 19, 2015
P=N/A, N=60, Not yet recruiting, Sponsor: Hampshire Hospitals NHS Foundation Trust
- Enrollment change, Trial termination: The Role of Traditional Chinese Medicine in the Treatment of Chronic Childhood Immune Thrombocytopenia (ITP) (clinicaltrials.gov) - Aug 19, 2015
P2/3, N=7, Terminated, Sponsor: Hadassah Medical Organization
N=20 --> 7 | Recruiting --> Terminated; Slow recruitment
- Zolinza (vorinostat) / Merck (MSD), alisertib (MLN8237) / Puma
Enrollment closed, Combination therapy, Epigenetic controller: Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma (clinicaltrials.gov) - Aug 19, 2015
P1, N=60, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
N=20 --> 7 | Recruiting --> Terminated; Slow recruitment Recruiting --> Active, not recruiting
- || MRX34 / Synlogic
Enrollment change, Trial primary completion date: A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection (clinicaltrials.gov) - Aug 18, 2015
P1, N=200, Recruiting, Sponsor: Mirna Therapeutics, Inc.
Recruiting --> Active, not recruiting N=120 --> 200 | Trial primary completion date: Dec 2015 --> Dec 2016
- Xyntha (moroctocog alfa) / Pfizer
P4 data, Phase classification: Post Marketing Surveillance To Observe Safety And Efficacy Of Xyntha® In Subjects With Hemophilia A (clinicaltrials.gov) - Aug 17, 2015
P=N/A, N=42, Completed, Sponsor: Pfizer
N=120 --> 200 | Trial primary completion date: Dec 2015 --> Dec 2016 Phase classification: P4 --> P=N/A
- ||||||| Promacta (eltrombopag) / Novartis
Trial completion, Trial primary completion date: EXTEND (Eltrombopag Extended Dosing Study) (clinicaltrials.gov) - Aug 17, 2015
P3, N=302, Completed, Sponsor: GlaxoSmithKline
Phase classification: P4 --> P=N/A Active, not recruiting --> Completed | Trial primary completion date: Feb 2015 --> Jul 2015
- mycophenolate mofetil / Generic mfg., sirolimus / Generic mfg.
Trial suspension: Inducible Regulatory T Cells (iTregs) in Non-Myeloablative Sibling Donor Peripheral Blood Stem Cell Transplantation (clinicaltrials.gov) - Aug 14, 2015
P1, N=22, Suspended, Sponsor: Masonic Cancer Center, University of Minnesota
Active, not recruiting --> Completed | Trial primary completion date: Feb 2015 --> Jul 2015 Recruiting --> Suspended
- Trial primary completion date: Fractionated Stem Cell Infusions in Myeloma Patients Undergoing Autologous Stem Cell Transplant (clinicaltrials.gov) - Aug 14, 2015
P=N/A, N=26, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Recruiting --> Suspended Trial primary completion date: Aug 2015 --> Aug 2016
- Trial completion, Enrollment change, Trial primary completion date: Therapeutic Research in Multiple Myeloma (clinicaltrials.gov) - Aug 14, 2015
P=N/A, N=6388, Completed, Sponsor: University of Arkansas
Trial primary completion date: Aug 2015 --> Aug 2016 Recruiting --> Completed | N=5000 --> 6388 | Trial primary completion date: Jul 2015 --> Mar 2015
- Trial primary completion date: Safety Study of Spray-Dried Solvent/Detergent-Treated Plasma for Infusion in Healthy Volunteers (clinicaltrials.gov) - Aug 14, 2015
P1, N=26, Recruiting, Sponsor: Entegrion, Inc.
Recruiting --> Completed | N=5000 --> 6388 | Trial primary completion date: Jul 2015 --> Mar 2015 Trial primary completion date: Jun 2015 --> Jun 2016
- methoxyamine (TRC102) / Tracon Pharma
Trial completion: Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies (clinicaltrials.gov) - Aug 14, 2015
P1, N=20, Completed, Sponsor: Case Comprehensive Cancer Center
Trial primary completion date: Jun 2015 --> Jun 2016 Active, not recruiting --> Completed
- Trial primary completion date: Exploration of Immune Response to Early PCV13 Vaccination in Conjunction With Autologous Transplant (clinicaltrials.gov) - Aug 14, 2015
P=N/A, N=8, Active, not recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Active, not recruiting --> Completed Trial primary completion date: Nov 2015 --> Feb 2015
- | Trial completion, Trial primary completion date: Thrombin Generation Numerical Models Validation in Haemophilic Case (clinicaltrials.gov) - Aug 14, 2015
P=N/A, N=40, Completed, Sponsor: Centre Hospitalier Universitaire de Saint Etienne
Trial primary completion date: Nov 2015 --> Feb 2015 Not yet recruiting --> Completed | Trial primary completion date: Jun 2016 --> Jul 2015
- Promacta (eltrombopag) / Novartis
Trial primary completion date: Eltrombopag for Thrombocytopenia in Patients With Relapsed Multiple Myeloma (clinicaltrials.gov) - Aug 13, 2015
P2, N=24, Active, not recruiting, Sponsor: Dana-Farber Cancer Institute
Not yet recruiting --> Completed | Trial primary completion date: Jun 2016 --> Jul 2015 Trial primary completion date: Jan 2015 --> Sep 2015
- Promacta (eltrombopag) / Novartis
Trial primary completion date: Effect of Eltrombopag Plus G-CSF on Human CD34+ Cell Mobilization in Multiple Myeloma Patients Undergoing ASCT (clinicaltrials.gov) - Aug 13, 2015
P=N/A, N=16, Recruiting, Sponsor: Dana-Farber Cancer Institute
Trial primary completion date: Jan 2015 --> Sep 2015 Trial primary completion date: Dec 2014 --> Dec 2016
- Trial primary completion date, HEOR: Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer (clinicaltrials.gov) - Aug 13, 2015
P=N/A, N=80, Active, not recruiting, Sponsor: Comprehensive Cancer Center of Wake Forest University
Trial primary completion date: Dec 2014 --> Dec 2016 Trial primary completion date: Oct 2011 --> Feb 2012
- Trial primary completion date: TMI-ASCT: Total Marrow Irradiation & Autologous Stem Cell Transplantation for Relapsed or Refractory Myeloma (clinicaltrials.gov) - Aug 13, 2015
P1/2, N=27, Recruiting, Sponsor: Ottawa Hospital Research Institute
Trial primary completion date: Oct 2011 --> Feb 2012 Trial primary completion date: Nov 2012 --> Nov 2020
- Imbruvica (ibrutinib) / AbbVie, J&J
Trial termination, Trial primary completion date: Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection (clinicaltrials.gov) - Aug 13, 2015
P1, N=72, Terminated, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Nov 2012 --> Nov 2020 Recruiting --> Terminated | Trial primary completion date: Aug 2017 --> Jul 2015; Inadequate accrual rate
- Stimuvax (tecemotide) / EMD Serono, Ono Pharma
Trial termination: EMR 63325-011: Common Safety Follow-up Trial of Tecemotide (L-BLP25) (clinicaltrials.gov) - Aug 13, 2015
P=N/A, N=20, Terminated, Sponsor: Merck KGaA
Recruiting --> Terminated | Trial primary completion date: Aug 2017 --> Jul 2015; Inadequate accrual rate Active, not recruiting --> Terminated; The study is terminated prematurely as the sponsor decided to discontinue program with Tecemotide in NSCLC.
- busulfan / Generic mfg.
Trial completion, Trial primary completion date: Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Cell Transplant (clinicaltrials.gov) - Aug 13, 2015
P0, N=33, Completed, Sponsor: Case Comprehensive Cancer Center
Active, not recruiting --> Terminated; The study is terminated prematurely as the sponsor decided to discontinue program with Tecemotide in NSCLC. Active, not recruiting --> Completed | Trial primary completion date: Jul 2015 --> Jan 2015
- fludarabine IV / Generic mfg., busulfan / Generic mfg.
Enrollment closed: Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer (clinicaltrials.gov) - Aug 13, 2015
P1/2, N=225, Active, not recruiting, Sponsor: OHSU Knight Cancer Institute
Active, not recruiting --> Completed | Trial primary completion date: Jul 2015 --> Jan 2015 Recruiting --> Active, not recruiting
- Trial completion: Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma (clinicaltrials.gov) - Aug 13, 2015
P2, N=60, Completed, Sponsor: Alliance for Clinical Trials in Oncology
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- blisibimod (A-623) / Anthera Pharma
Enrollment change, Trial withdrawal: MONICA-SC: A Study to Evaluate the Efficacy, Safety and Tolerability of Blisibimod (A-623) Administration in Subjects With ITP (clinicaltrials.gov) - Aug 12, 2015
P2/3, N=0, Withdrawn, Sponsor: Anthera Pharmaceuticals
Active, not recruiting --> Completed N=60 --> 0 | Not yet recruiting --> Withdrawn
- ||| Kogenate FS (octocog alfa sucrose formulation) / CSL Behring, Bayer
Trial completion, Enrollment change: OPTIMS: Validation Study of a cOmputer Pharmacokinetic Tool to assIst in the Follow up Care of haeMophilia A Patients (clinicaltrials.gov) - Aug 12, 2015
P=N/A, N=69, Completed, Sponsor: Bayer
N=60 --> 0 | Not yet recruiting --> Withdrawn Active, not recruiting --> Completed | N=100 --> 69
- || Retacrit (epoetin alfa-epbx) / Stada, Norbitec, Pfizer
Enrollment change: Biosimilar Retacrit (clinicaltrials.gov) - Aug 12, 2015
P=N/A, N=291, Completed, Sponsor: Hospira, Inc.
Active, not recruiting --> Completed | N=100 --> 69 N=240 --> 291
- alteminostat (CKD-581) / Chong Kun Dang
Enrollment open, Enrollment change, Trial initiation date, Trial primary completion date: Safety and Pharmacokinetic Profile of CKD-581 (clinicaltrials.gov) - Aug 12, 2015
P1, N=40, Recruiting, Sponsor: Chong Kun Dang Pharmaceutical
N=240 --> 291 Active, not recruiting --> Recruiting | N=24 --> 40 | Initiation date: Dec 2011 --> May 2012 | Trial primary completion date: May 2012 --> Jun 2016
- Trial completion: METRO: Study of Thrombin Generation During the 3 First Cycles of Chemotherapy in Patients With Newly Diagnosed Multiple Myeloma (clinicaltrials.gov) - Aug 12, 2015
P=N/A, N=71, Completed, Sponsor: Centre Hospitalier Universitaire de Saint Etienne
Active, not recruiting --> Recruiting | N=24 --> 40 | Initiation date: Dec 2011 --> May 2012 | Trial primary completion date: May 2012 --> Jun 2016 Recruiting --> Completed
- MK-2206 / Merck (MSD)
Trial completion, Enrollment change, Trial primary completion date: Akt Inhibitor MK2206 in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (clinicaltrials.gov) - Aug 12, 2015
P2, N=22, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed Recruiting --> Completed | N=51 --> 22 | Trial primary completion date: May 2015 --> Jun 2013
- Trial completion, Post-transplantation: Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies (clinicaltrials.gov) - Aug 12, 2015
P2, N=44, Completed, Sponsor: Fred Hutchinson Cancer Research Center
Recruiting --> Completed | N=51 --> 22 | Trial primary completion date: May 2015 --> Jun 2013 Active, not recruiting --> Completed
- lenalidomide / Generic mfg.
Trial completion: REVALLO: Lenalidomide After Reduced-intensity Allogeneic Stem Cell Transplantation for Relapsed Multiple Myeloma (clinicaltrials.gov) - Aug 12, 2015
P1, N=13, Completed, Sponsor: University Hospital, Bordeaux
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Enrollment open: Human Fibrinogen Concentrate (FGTW) in Pediatric Patients With Congenital Fibrinogen Deficiency (clinicaltrials.gov) - Aug 12, 2015
P2/3, N=16, Recruiting, Sponsor: Laboratoire français de Fractionnement et de Biotechnologies
Active, not recruiting --> Completed Active, not recruiting --> Recruiting
- Onureg (azacitidine oral) / BMS
Enrollment change, Trial termination, Trial primary completion date: Phase 1 Study of CC-486 in Japanese Subjects With Hematological Neoplasms (clinicaltrials.gov) - Aug 11, 2015
P1, N=2, Terminated, Sponsor: Celgene Corporation
Active, not recruiting --> Recruiting N=30 --> 2 | Recruiting --> Terminated | Trial primary completion date: Mar 2017 --> Jul 2015; Due to Slow Accrual study was terminated.
- bortezomib / Generic mfg., dexamethasone / Generic mfg., lenalidomide / Generic mfg.
Enrollment closed, Trial primary completion date: RVD Lite: Lenalidomide/Bortezomib/Dexamethasone for Multiple Myeloma (MM) (clinicaltrials.gov) - Aug 11, 2015
P2, N=50, Active, not recruiting, Sponsor: Massachusetts General Hospital
N=30 --> 2 | Recruiting --> Terminated | Trial primary completion date: Mar 2017 --> Jul 2015; Due to Slow Accrual study was terminated. Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2015 --> Dec 2015
- Darzalex (daratumumab) / J&J
Enrollment closed, Enrollment change: A Study of Daratumumab in Japanese Participants With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Aug 11, 2015
P1, N=9, Active, not recruiting, Sponsor: Janssen Pharmaceutical K.K.
Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2015 --> Dec 2015 Recruiting --> Active, not recruiting | N=12 --> 9
- ||||||| Anathromb (anagrelide CR) / AOP Orphan Pharma
Trial completion, Trial primary completion date: TEAM-ET: Anagrelide Retard in Essential Thrombocythemia (clinicaltrials.gov) - Aug 11, 2015
P3, N=106, Completed, Sponsor: AOP Orphan Pharmaceuticals AG
Recruiting --> Active, not recruiting | N=12 --> 9 Active, not recruiting --> Completed | Trial primary completion date: Jun 2015 --> Feb 2015
- Mekinist (trametinib) / Novartis, BeiGene
Enrollment open, Trial initiation date: UARK 2014-08 A Phase II Open-Label, Multiple-Dose, Single Agent Study to Evaluate the Overall Response Rate of Orally Administered Trametinib (clinicaltrials.gov) - Aug 6, 2015
P2, N=23, Recruiting, Sponsor: University of Arkansas
Active, not recruiting --> Completed | Trial primary completion date: Jun 2015 --> Feb 2015 Not yet recruiting --> Recruiting | Initiation date: Aug 2015 --> Mar 2015
- | Mozobil (plerixafor) / Sanofi
Trial completion: Plerixafor Plus Granulocyte Colony-stimulating Factor (G-CSF) For Mobilization And Collection Of Peripheral Hematopoietic Stem Cells In Japanese Participants With Multiple Myeloma (clinicaltrials.gov) - Aug 5, 2015
P2, N=14, Completed, Sponsor: Genzyme, a Sanofi Company
Not yet recruiting --> Recruiting | Initiation date: Aug 2015 --> Mar 2015 Active, not recruiting --> Completed
- New P2 trial: Related Hematopoietic Stem Cell Transplantation (HSCT) for Genetic Diseases of Blood Cells (clinicaltrials.gov) - Jul 31, 2015
P2, N=20, Completed, Sponsor: Children's Hospital Los Angeles
- Kovaltry (octocog alfa) / Bayer, CSL Behring
Enrollment closed: Single Dose Study in Subjects With Severe Hemophilia A Comparing Pharmacokinetic Parameters for BAY81-8973 and Advate (clinicaltrials.gov) - Jul 29, 2015
P1, N=18, Active, not recruiting, Sponsor: Bayer
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Kovaltry (octocog alfa) / Bayer, CSL Behring
Enrollment open: Single Dose Study in Subjects With Severe Hemophilia A Comparing Pharmacokinetic Parameters for BAY81-8973 and Advate (clinicaltrials.gov) - Jul 25, 2015
P1, N=18, Recruiting, Sponsor: Bayer
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- desmopressin / Generic mfg.
New P1 trial: Characterization of Laboratory Response to DDAVP in Adult Hemophilia A Carriers (clinicaltrials.gov) - Jul 22, 2015
P1, N=25, Enrolling by invitation, Sponsor: Emory University
- Kcentra (plasma-derived prothrombin complex concentrate) / CSL Behring
Trial primary completion date: Study of a Prothrombin Complex Concentrate for Rapid Reversal of Coagulopathy Induced by Vitamin K Antagonists in Japanese Subjects (clinicaltrials.gov) - Jul 21, 2015
P3, N=10, Recruiting, Sponsor: CSL Behring
Not yet recruiting --> Recruiting Trial primary completion date: Jul 2015 --> Oct 2015
- Biomarker, Trial completion: Biomarkers in Vascular Ehlers-Danlos Syndrome (clinicaltrials.gov) - Jul 21, 2015
P=N/A, N=211, Completed, Sponsor: Assistance Publique - Hôpitaux de Paris
Trial primary completion date: Jul 2015 --> Oct 2015 Recruiting --> Completed
- ||||||| dexamethasone / Generic mfg., melphalan / Generic mfg.
Trial completion, Enrollment change: Low-Dose Melphalan and Dexamethasone Compared With High-Dose Melphalan Followed By Autologous Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis (clinicaltrials.gov) - Jul 21, 2015
P3, N=89, Completed, Sponsor: Mayo Clinic
Recruiting --> Completed Active, not recruiting --> Completed | N=152 --> 89
- danazol oral / Generic mfg.
Trial primary completion date: Safety Study of Danazol With Plasma Exchange and Steroids for the Treatment of Thrombotic Thrombocytopenic Purpura (TTP) (clinicaltrials.gov) - Jul 20, 2015
P2, N=25, Recruiting, Sponsor: Beth Israel Medical Center
Active, not recruiting --> Completed | N=152 --> 89 Trial primary completion date: Dec 2015 --> Dec 2020
- | Xyntha (moroctocog alfa) / Pfizer
Phase classification, Adverse events: Study Evaluating Pharmacovigilance Of Refacto AF (clinicaltrials.gov) - Jul 17, 2015
P=N/A, N=140, Recruiting, Sponsor: Pfizer
Trial primary completion date: Dec 2015 --> Dec 2020 Phase classification: P4 --> P=N/A
- ||| Kogenate FS (octocog alfa sucrose formulation) / CSL Behring, Bayer
Trial completion, Enrollment change: Retrospective Study in Chinese Pediatric Hemophilia A Patients With rFⅧ Contained Regular Prophylaxis (clinicaltrials.gov) - Jul 17, 2015
P=N/A, N=181, Completed, Sponsor: Bayer
Phase classification: P4 --> P=N/A Recruiting --> Completed | N=300 --> 181
- ||| Darzalex IV (daratumumab) / J&J
Clinical: Daratumumab (HuMax®-CD38) Safety Study in Multiple Myeloma (clinicaltrials.gov) - Jul 17, 2015
P2, N=104, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
Recruiting --> Completed | N=300 --> 181 Phase classification: P1/2 --> P2 | Initiation date: Dec 2007 --> Mar 2008 | Trial primary completion date: Jan 2016 --> Dec 2016
- rVIIa-FP (CSL689) / CSL Behring
Enrollment open: Study of the Pharmacokinetics and Safety of Recombinant Factor VIIa Fusion Protein (rVIIa-FP, CSL689) in Patients With Congenital Factor VII Deficiency (clinicaltrials.gov) - Jul 17, 2015
P1, N=16, Recruiting, Sponsor: CSL Behring
Phase classification: P1/2 --> P2 | Initiation date: Dec 2007 --> Mar 2008 | Trial primary completion date: Jan 2016 --> Dec 2016 Not yet recruiting --> Recruiting
- ||| bortezomib / Generic mfg.
Enrollment closed, Trial primary completion date, Residual disease, Minimal residual disease: First Autologous Transplant on Minimal Residual Disease Markers in Previously Untreated Myeloma Undergoing Initial Treatment With Velcade (clinicaltrials.gov) - Jul 17, 2015
P2, N=100, Active, not recruiting, Sponsor: Vanderbilt-Ingram Cancer Center
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial primary completion date: May 2017 --> Dec 2015